SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Business
Fasten Your Seatbelt: Biogen Preps for a Deal-Making Bonanza
April 24, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Deals
How Biogen Lost Its Chance to Be the Hunter and Became the Hunted in Just a Few Months
April 17, 2017
 · 
4 min read
Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study
Business
Bristol-Myers Squibb Inks Two Separate Pacts With Biogen and Roche For a Total of Up to $1.1B
April 13, 2017
 · 
3 min read
Business
How Much Biogen’s Top-Selling MS Drug Sales Could Fall by 2020
April 10, 2017
 · 
1 min read
How Biogen Makes Most of Its Cash
Drug Development
A Look at Biogen’s Big Bet on the Holy Grail of Science—Alzheimer’s
March 28, 2017
 · 
2 min read
How Biogen Makes Most of Its Cash
Business
Biogen Loses Gene Therapy Pioneer to REGENXBIO
March 28, 2017
 · 
3 min read
How Biogen Makes Most of Its Cash
Genetown
How Biogen Spinoff Bioverativ and Its Hemophilia Med Could Make This Biotech Bleed
March 23, 2017
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Policy
Biogen’s Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target
March 22, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Genetown
Biogen Faces Biggest One-Day Drop
March 17, 2017
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More